Sigma ligands for neuronal regeneration and functional recovery

Details Sigma ligands for neuronal regeneration and functional recovery Sigma ligands for neuronal regeneration and functional recovery

2011-01-04

2011-01-04

Marschel, Ardin (Department: 1613)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S247000, C514S248000, C514S282000

Reexamination Certificate

active

07863272

ABSTRACT:
The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably SA-4503, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by ischemic stroke, diabetic peripheral neuropathy, cancer therapy induced neuropathy, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, Huntington's disease or Parkinson's disease. In other methods, the sigma receptor ligands are administered after stroke to facilitate functional recovery. The administration of the sigma receptor ligands effects faster functional recovery.

REFERENCES:
patent: 5055470 (1991-10-01), Boissard et al.
patent: 5229394 (1993-07-01), Salazar-Grueso
patent: 5665725 (1997-09-01), Moltzen et al.
patent: 5736546 (1998-04-01), Kawashima et al.
patent: 6087346 (2000-07-01), Glennon et al.
patent: 6436938 (2002-08-01), Howard, Jr.
patent: 2003/0087840 (2003-05-01), Lai et al.
patent: 2005/0032827 (2005-02-01), Oksenberg et al.
patent: 2006/0014753 (2006-01-01), Shamloo et al.
patent: 2006/0052386 (2006-03-01), Wieloch et al.
patent: WO/91/03243 (1991-03-01), None
patent: WO/93/09094 (1993-03-01), None
patent: WO/94/24116 (1994-01-01), None
patent: WO/96/05185 (1996-02-01), None
patent: WO/99/24436 (1999-05-01), None
patent: WO/01/74359 (2001-10-01), None
Kidwell et al. (Stroke 2001, 32: 1349-1359).
Cheng et al. (“Neuroprotection for ischemic stroke,” NeuroRx Jan. 2004, vol. 1, 36-45).
Pollack & Disler (“Rehabilitation of patients after stroke,” The Medical Journal of Australia 2002, 177(8): 452-456).
Long et al., “Selective Sigma Ligands Protect Against Dynorphin A-Induced Spinal Cord Injury in Rats,”Society for Neuroscience Abstracts, vol. 16, 1990, No. 461.4.
Fujimura et al., “Synthesis, Structure and Quantitative Structure-Activity Relationships of σ Receptor Ligands, 1-[2-(3,4-Dimethyxyphenyl)ethyl]-4-(3-phenylpropyl) piperazines,”Bioorganic and Medicinal Chemistry, vol. 5, No. 8, 1997, pp. 1675-1683.
Lobner, Doug and Lipton, Peter, “σ-Ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia”, Neuroscience Letters, 1990, pp. 169-174, Elsevier Scientific Publishers, Ireland.
Manallack, David T. and Beart Philip M., “Quantitative conformational analyses predict distinct receptor sites for PCP-like and σ drugs”, European Journal of Pharmacology, 1987, pp. 231-235, Elsevier.
Perregaard, Jens, “σ-Ligands with Subnanomolar Affinity and Preference for the σ2Binding Site. 1. 3-(ω-Aminoalkyl)-1H-indoles”, Journal of Medicinal Chemistry, 1995, pp. 1998-2008, vol. 38, No. 11.
Pontecorvo, Michael J., “Possible Cerebroprotective and In Vivo NMDA Antagonist Activities of Sigma Agents”, Brain Research Bulletin, 1991, pp. 461-465, vol. 26, Pergamon Press, United States.
Senda, Toshihiko, “Effect of SA4503, a novel σ1receptor agonist, against glutamate neurotoxicity in cultured rat retinal neurons”, European Journal of Pharmacology, 1998, pp. 105-111, Elsevier.
Miyaoka et al., “Fluvoxamine for the Treatment of Depression and Parkinsonism in Progressive Supranuclear Palsy”, International Journal of Psychiatry in Clinical Practice, 2002, pp. 45-47, vol. 6, No. 1.
Tottori, et al., “Attenuation of Scopolamine-Induced and Age-Associated Memory Impairments by the Sigma and\ 5-hydroxytryptamine1A receptor agonist OPC-14523”, Journal of Pharmacology and Experimental Therapeutics, 2002, pp. 249-257, vol. 301, No. 1.
Tucker et al., “Fluvoxamine Reduces Physiologic Reactivity to Trauma Scripts in Posttraumatic Stress Disorder”, Journal of Clinical Psychopharmacology, 2000, pp. 367-372, vol. 20, No. 3.
Shuaib et al., NEJM, 357(6): 562-571 (Aug. 2007).
Endres et al., Cerebrovasc. Dis., 25: 268-78 (2008).
Arvidsson et al., Nat. Med., 8(9): 963-70 (Sep. 2002).
Johansson et al., J. Cereb. Blood Flow & Metab., 22: 89-96 (2002).
Metz et al., Behavioural Brain Research, 162:71-82 (2005).
Dancause et al., J. Neuroscience, 25(44): 10167-79 (Nov. 2005).
Zhang et al., Stroke, 36: 847-52 (2005).
Lee et al., J. Neuroscience, 24(27): 6209-17 (Jul. 2004).
Chen et al., PNAS USA, 99: 9031-36 (2002).
Wieloch et al, Curr. Opin. Neurobiology, 6: 1-7 (2006, article in press).
Martin et al., Trends Neuroscience, 17: 251-57 (1994).
Dingledine et al., Pharmacol. Rev., 51(1): 7-61 (1999).
Zlokovic, Nat. Med., 12: 390-1 (2006).
Maurice, T., Drug News and Perspectives, 15(10): 617-25 (2002).
Maurice et al., Brit. J. Pharmacol., 127(2): 335-42 (May 1999).
Takahashi et al., Stroke, 26(9): 1676-82 (1995).
Earley et al., Neurochem. Internatl., 28(5-6): 509-21 (1996).
Matsuno et al., CNS Drug Rev., 4(1): 1-24 (1998).
Heading, C., Curr. Opin. Invest. Drugs, 2(2): 266-70 (2001).
Nakazawa et al., Neurochem. Internatl., 32: 337-43 (1998).
Chen, et al., Ann.Neurol., 53: 743-51 (2003).
Hoffman, et al., Program# 381.1/AA12, 2007 Neuroscience Meeting Planner, Society for Neuroscience (2007).

Affiliated with

Also associated with

Rating

Sigma ligands for neuronal regeneration and functional recovery does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sigma ligands for neuronal regeneration and functional recovery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sigma ligands for neuronal regeneration and functional recovery will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2706274